MA29663B1 - Modification du facteur fviii en fonction du site - Google Patents

Modification du facteur fviii en fonction du site

Info

Publication number
MA29663B1
MA29663B1 MA29972A MA29972A MA29663B1 MA 29663 B1 MA29663 B1 MA 29663B1 MA 29972 A MA29972 A MA 29972A MA 29972 A MA29972 A MA 29972A MA 29663 B1 MA29663 B1 MA 29663B1
Authority
MA
Morocco
Prior art keywords
site
modification
factor according
fviii
fviii factor
Prior art date
Application number
MA29972A
Other languages
English (en)
French (fr)
Inventor
Clark Q Pan
John E Murphy
Baisong Mei
Jonathan S Strauss
Hendri Tjandra
Jianmin Chen
Thomas Barnett
Liang Tang
Deqian Wang
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36337298&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29663(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of MA29663B1 publication Critical patent/MA29663B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
MA29972A 2004-11-12 2007-06-06 Modification du facteur fviii en fonction du site MA29663B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62727704P 2004-11-12 2004-11-12

Publications (1)

Publication Number Publication Date
MA29663B1 true MA29663B1 (fr) 2008-08-01

Family

ID=36337298

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29972A MA29663B1 (fr) 2004-11-12 2007-06-06 Modification du facteur fviii en fonction du site

Country Status (32)

Country Link
US (4) US7632921B2 (forum.php)
EP (9) EP3130601B1 (forum.php)
JP (5) JP2008524117A (forum.php)
KR (7) KR101654011B1 (forum.php)
CN (6) CN101124331B (forum.php)
AU (1) AU2005304622B2 (forum.php)
BE (1) BE2019C523I2 (forum.php)
BR (2) BR122016022033B8 (forum.php)
CA (1) CA2586379C (forum.php)
CY (3) CY1119292T1 (forum.php)
DK (3) DK2363414T3 (forum.php)
ES (4) ES2930159T3 (forum.php)
FR (1) FR19C1031I2 (forum.php)
HN (1) HN2007015683A (forum.php)
HR (2) HRP20070268B1 (forum.php)
HU (5) HUE060016T2 (forum.php)
IL (3) IL182903A (forum.php)
LT (5) LT3130601T (forum.php)
LU (1) LUC00118I2 (forum.php)
MA (1) MA29663B1 (forum.php)
MX (3) MX350293B (forum.php)
NL (1) NL300989I2 (forum.php)
NO (3) NO345800B1 (forum.php)
NZ (1) NZ555032A (forum.php)
PH (2) PH12014500352B1 (forum.php)
PL (3) PL1824988T3 (forum.php)
PT (4) PT3130601T (forum.php)
RU (1) RU2423380C2 (forum.php)
SI (4) SI2363414T1 (forum.php)
UA (1) UA95225C2 (forum.php)
WO (1) WO2006053299A2 (forum.php)
ZA (1) ZA200703696B (forum.php)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1615945B1 (en) 2003-04-09 2011-09-28 BioGeneriX AG Glycopegylation methods and proteins/peptides produced by the methods
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
JP2008505119A (ja) 2004-06-30 2008-02-21 ネクター セラピューティクス アラバマ，コーポレイション 高分子−第ｉｘ因子部分の抱合体
EP1771066A2 (en) 2004-07-13 2007-04-11 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1
WO2006050247A2 (en) 2004-10-29 2006-05-11 Neose Technologies, Inc. Remodeling and glycopegylation of fibroblast growth factor (fgf)
MX350293B (es) 2004-11-12 2017-09-04 Bayer Healthcare Llc Modificacion dirigida al sitio del factor viii.
JP4951527B2 (ja) 2005-01-10 2012-06-13 バイオジェネリックス アーゲー 糖ｐｅｇ化顆粒球コロニー刺激因子
EP1871795A4 (en) 2005-04-08 2010-03-31 Biogenerix Ag COMPOSITIONS AND METHOD FOR PRODUCING GLYCOSYLATION MUTANTS OF A PROTEASE-RESISTANT HUMAN GROWTH HORMONE
EP1893632B1 (en) 2005-06-17 2015-08-12 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
CN101484576A (zh) * 2006-05-24 2009-07-15 诺沃-诺迪斯克保健股份有限公司 具有延长的体内半寿期的因子ix类似物
CN101516388B (zh) 2006-07-21 2012-10-31 诺和诺德公司 通过o-联糖基化序列的肽的糖基化
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
ES2655639T3 (es) 2006-12-15 2018-02-21 Baxalta GmbH Conjugado de factor VIIa - ácido (poli)siálico que tiene una semivida in vivo prolongada
PL2144923T3 (pl) 2007-04-03 2013-12-31 Biogenerix Ag Sposoby leczenia z użyciem glikopegilowanego G-CSF
CN101778859B (zh) 2007-06-12 2014-03-26 诺和诺德公司 改良的用于生产核苷酸糖的方法
EP2222329A1 (en) * 2007-11-09 2010-09-01 Baxter International Inc. Modified recombinant factor viii and von willebrand factor and methods of use
US20130189239A1 (en) * 2008-02-27 2013-07-25 Novo Nordisk A/S Conjugated Factor VIII Molecules
EP2288365A4 (en) * 2008-05-16 2012-05-09 Bayer Healthcare Llc TARGETED COOLING FACTORS AND METHOD OF APPLICATION THEREFOR
MX2010013219A (es) * 2008-06-04 2011-04-11 Bayer Healthcare Llc Muteínas de fviii para el tratamiento de la enfermedad de von willebrand.
ES2531464T3 (es) 2008-06-24 2015-03-16 Csl Behring Gmbh Factor VIII, factor de von Willebrand o sus complejos con semivida in vivo prolongada
WO2010019263A2 (en) * 2008-08-15 2010-02-18 Genzyme Corporation Soluble flt constructs for treating cancers
HUE039906T2 (hu) * 2008-10-17 2019-02-28 Baxalta GmbH Alacsony fokú vízben oldható polimer tartalmú módosított vérfaktorok
US20120027743A1 (en) * 2008-11-03 2012-02-02 Bayer Healthcare Llc Method for the Treatment of Hemophilia
JP2012510060A (ja) * 2008-11-24 2012-04-26 バイエル・ヘルスケア・エルエルシー シリカをベースとする活性化部分トロンボプラスチン時間アッセイにおけるｐｅｇ化血液凝固因子の活性の測定方法
US20120121613A1 (en) * 2009-01-19 2012-05-17 Bayer Healthcare Llc Protein conjugate having an endopeptidase- cleavable bioprotective moiety
ES2610356T3 (es) 2009-02-03 2017-04-27 Amunix Operating Inc. Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos
CN102333788A (zh) * 2009-02-19 2012-01-25 诺沃—诺迪斯克有限公司 因子viii的修饰
HUE030373T2 (en) * 2009-03-20 2017-05-29 Hanmi Science Co Ltd A method for producing a site-specific conjugate of a physiologically active polypeptide
CA2756197A1 (en) * 2009-03-24 2010-09-30 Bayer Healthcare Llc Factor viii variants and methods of use
AU2010281453C1 (en) 2009-07-27 2019-08-15 Takeda Pharmaceutical Company Limited Blood coagulation protein conjugates
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
SG178051A1 (en) 2009-07-27 2012-03-29 Lipoxen Technologies Ltd Glycopolysialylation of non-blood coagulation proteins
SG10201401194VA (en) 2009-07-27 2014-07-30 Lipoxen Technologies Ltd Glycopolysialylation of non-blood coagulation proteins
CA2772051C (en) 2009-08-24 2020-08-18 Amunix Operating Inc. Coagulation factor ix compositions and methods of making and using same
SG10201907152YA (en) 2009-12-06 2019-09-27 Bioverativ Therapeutics Inc Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
CN102770449B (zh) 2010-02-16 2016-02-24 诺沃—诺迪斯克有限公司 具有降低的vwf结合的因子viii分子
AU2011217794B2 (en) * 2010-02-21 2015-01-29 Bayer Healthcare Llc Method for activation and conjugation of biomolecules
JP2013534931A (ja) 2010-04-15 2013-09-09 オリガシス 高分子量双性イオン含有重合体
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
GB201007357D0 (en) * 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
EP3508573A1 (en) * 2010-07-09 2019-07-10 Bioverativ Therapeutics Inc. Systems for factor viii processing and methods thereof
WO2012061689A2 (en) * 2010-11-05 2012-05-10 Ipsen Pharma S.A.S. A new variant of antihemophilic factor viii having increased specific activity
US20130345403A1 (en) * 2010-12-16 2013-12-26 Novo Nordisk A/S Aqueous factor viii solution
HUE049352T2 (hu) 2010-12-22 2020-09-28 Baxalta GmbH Anyagok és módszerek egy vízoldható zsírsavszármazéknak egy fehérjéhez való konjugálására
EP2714093A1 (en) * 2011-05-27 2014-04-09 Baxter International Inc. Therapeutic proteins with increased half-life and methods of preparing same
EP2717898B1 (en) 2011-06-10 2018-12-19 Bioverativ Therapeutics Inc. Pro-coagulant compounds and methods of use thereof
BR112014000055A2 (pt) 2011-07-01 2017-06-13 Bayer Ip Gmbh polipeptídeos de fusão de relaxina e usos dos mesmos
PT2729161T (pt) 2011-07-08 2019-04-01 Bioverativ Therapeutics Inc Polipéptidos fator viii híbridos e quiméricos, e métodos de utilização dos mesmos
RU2017101333A (ru) 2011-09-23 2018-12-19 Ново Нордиск А/С Новые аналоги глюкагона
KR20130049671A (ko) * 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
EP3549953A1 (en) * 2012-02-15 2019-10-09 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
EP2814502B1 (en) 2012-02-15 2017-09-13 CSL Behring GmbH Von willebrand factor variants having improved factor viii binding affinity
PL3564260T3 (pl) 2012-02-15 2023-03-06 Bioverativ Therapeutics Inc. Kompozycje czynnika viii oraz sposoby ich wytwarzania i stosowania
EP2666782A1 (en) * 2012-05-22 2013-11-27 Imnate Sarl Coagulation factor VIII with reduced immunogenicity.
CN104519897A (zh) 2012-06-08 2015-04-15 比奥根艾迪克Ma公司 促凝血化合物
EP2870250B2 (en) 2012-07-06 2022-06-29 Bioverativ Therapeutics Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
EP2908847B1 (en) 2012-10-18 2022-03-30 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
WO2014070953A1 (en) 2012-10-30 2014-05-08 Biogen Idec Ma Inc. Methods of Using FVIII Polypeptide
SG11201505926VA (en) 2013-03-15 2015-09-29 Biogen Ma Inc Factor ix polypeptide formulations
HK1213273A1 (zh) * 2013-03-15 2016-06-30 拜耳医药保健有限公司 重組因子viii製劑
JP6330026B2 (ja) 2013-03-15 2018-05-23 バイオベラティブ セラピューティクス インコーポレイテッド 第ｖｉｉｉ因子ポリペプチド製剤
MX362275B (es) 2013-04-18 2019-01-10 Novo Nordisk As Co-agonista de peptido similar a glucagon tipo 1 (glp-1) receptor de glucagon de larga duracion, estables para uso medico.
EP2796145B1 (en) 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
TW201519900A (zh) * 2013-04-28 2015-06-01 Bayer Healthcare Llc 用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法
TWI667255B (zh) 2013-08-14 2019-08-01 美商生物化學醫療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
WO2015023894A1 (en) 2013-08-14 2015-02-19 Biogen Idec Ma Inc. Recombinant factor viii proteins
JP6463361B2 (ja) 2013-09-08 2019-01-30 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． 第ｖｉｉｉ因子両性イオンポリマーコンジュゲート
EA201690817A1 (ru) * 2013-10-22 2016-08-31 Дбв Текнолоджиз Способ лечения гемофилии индукцией толерантности к факторам крови
EP3065769A4 (en) 2013-11-08 2017-05-31 Biogen MA Inc. Procoagulant fusion compound
RU2546297C1 (ru) * 2013-11-19 2015-04-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук Средство, улучшающее реологические свойства крови
ES2967617T3 (es) 2013-12-06 2024-05-03 Bioverativ Therapeutics Inc Herramientas de farmacocinética poblacional y sus usos
DK3097118T3 (en) 2014-01-20 2018-11-05 Octapharma Ag PROCEDURE FOR MANUFACTURING FACTOR VIII WITH AN IMPROVED FVIII: C / FVIII: AG RELATIONSHIP
AU2015214245B2 (en) 2014-02-04 2020-09-10 Biogen Ma Inc. Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
WO2015132724A1 (en) * 2014-03-05 2015-09-11 Pfizer Inc. Improved muteins of clotting factor viii
JP7058940B2 (ja) 2014-03-24 2022-04-25 バイオベラティブ セラピューティクス インコーポレイテッド 凍結乾燥第ｉｘ因子製剤
CA2944909A1 (en) * 2014-04-04 2015-10-08 Bloodworks Routine laboratory and point-of-care (poc) testing for hemostasis
AU2015243961A1 (en) 2014-04-10 2016-10-27 Bayer Healthcare Llc Compounded media powder formulation and method of preparation of liquid medium for cell culture
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
KR20170026580A (ko) 2014-07-02 2017-03-08 씨에스엘 리미티드 변형된 폰 빌레브란트 인자
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
JP2018510212A (ja) 2015-03-06 2018-04-12 ツェー・エス・エル・ベーリング・レコンビナント・ファシリティ・アクチエンゲゼルシャフト 向上した半減期を有する改変したフォンヴィレブランド因子
JP6651548B2 (ja) 2015-05-22 2020-02-19 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 改変フォン・ヴィルブランド因子を製造するための方法
SG10201910896UA (en) 2015-05-22 2020-01-30 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for treating hemophilia
TWI741992B (zh) 2015-08-03 2021-10-11 美商百歐維拉提夫治療公司 因子ｉｘ融合蛋白以及其製備及使用方法
US9849125B1 (en) 2015-11-03 2017-12-26 Banner Lifie Sciences LLC Anti-overingestion dosage forms
AU2017204955B2 (en) 2016-01-07 2021-04-01 CSL Behring Lengnau AG Mutated truncated von Willebrand Factor
BR112018013822A2 (pt) 2016-01-07 2018-12-11 Csl Behring Recombinant Facility Ag ?polipeptídeo modificado, complexo, composição farmacêutica, métodos para tratamento de um distúrbio hemorrágico, para produção de um polipeptídeo e para aumento da meia-vida do fator viii, uso de um polipeptídeo modificado, polinucleotídeo, plasmídeo ou vetor, e, célula hospedeira?
US20230151078A1 (en) * 2016-06-24 2023-05-18 Mogam Instiitute For Biomedical Research Recombinant single-chain fviii and chemical conjugate thereof
CN110381986B (zh) 2016-11-11 2023-08-18 康诺贝林伦瑙有限公司 用于血管外施予以治疗或预防凝血疾病的截短型冯维勒布兰德因子多肽
TW201828975A (zh) 2016-11-11 2018-08-16 瑞士商Ｃｓｌ貝林重組技能公司 用於治療血友病之截短型類血友病因子（ｖｏｎ Ｗｉｌｌｅｂｒａｎｄ ｆａｃｔｏｒ）多肽類
BR112019010034A2 (pt) 2016-11-16 2019-09-03 Bayer Healthcare Llc fator viii alvejado de hemácia e método de uso do mesmo
WO2018102743A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
BR112019011198A2 (pt) 2016-12-02 2019-12-17 Bioverativ Therapeutics Inc métodos de indução de tolerância imune a fatores de coagulação
CN110831613A (zh) 2017-01-31 2020-02-21 比奥维拉迪维治疗股份有限公司 因子ix融合蛋白及其制备和使用方法
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
KR20190086269A (ko) * 2018-01-12 2019-07-22 재단법인 목암생명과학연구소 체내 지속형 재조합 당단백질 및 이의 제조방법
LT3793588T (lt) 2018-05-18 2025-06-25 Bioverativ Therapeutics Inc. Hemofilijos a gydymo būdai
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
WO2021091881A1 (en) * 2019-11-04 2021-05-14 The Trustees Of Columbia University In The City Of New York High concentration cell penetrating caspase inhibitor conjugates compositions and methods thereof
WO2021113800A1 (en) * 2019-12-06 2021-06-10 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor viii function

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59172425A (ja) * 1983-03-18 1984-09-29 Nippon Chemiphar Co Ltd 新規な血液凝固因子誘導体およびその製造法ならびにそれを含有する血液凝固促進剤
US7138505B1 (en) 1984-01-12 2006-11-21 Novartis Vaccines And Diagnostics, Inc. Factor VIII:C nucleic acid molecules
US4970300A (en) 1985-02-01 1990-11-13 New York University Modified factor VIII
US5451521A (en) 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
EP0690126B1 (en) 1987-06-12 2001-11-28 Baxter Aktiengesellschaft Novel proteins with factor VIII activitiy: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
IL86693A (en) 1987-06-12 1994-06-24 Stichting Centraal Lab Proteins with factor VIII activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
AU2473388A (en) * 1987-11-16 1989-06-22 Scripps Clinic And Research Foundation Treatment of factor viii inhibitors
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US6037452A (en) 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
CA2124690C (en) 1992-10-02 2007-09-11 Thomas Osterberg Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
WO1994015625A1 (en) * 1993-01-15 1994-07-21 Enzon, Inc. Factor viii - polymeric conjugates
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
WO1995011987A1 (en) 1993-10-29 1995-05-04 Incyte Pharmaceuticals, Inc. Chimeric proteins including protease nexin-1 variants
IL113010A (en) 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
BE1008491A3 (fr) * 1994-07-14 1996-05-07 Croix Rouge De Belgique Depart Sequence polypeptidique antigenique du facteur viii, fragments et/ou epitopes de celle-ci.
CA2204726A1 (en) 1994-11-09 1996-12-27 Robin E. Offord Functionalized polymers for site-specific attachment
AU691111B2 (en) * 1995-06-21 1998-05-07 Google Technology Holdings LLC Method and antenna for providing an omnidirectional pattern
AU6486196A (en) 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs with altered protease sites
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
AT403438B (de) 1996-05-24 1998-02-25 Immuno Ag Pharmazeutische präparation mit faktor viii prokoagulationsaktivität und vwf-bindungsaktivität
US6458563B1 (en) * 1996-06-26 2002-10-01 Emory University Modified factor VIII
SI0964702T1 (sl) * 1996-08-02 2007-02-28 Ortho Mcneil Pharm Inc Polipeptidi, ki imajo posamezen kovalentno vezan N-terminalni vodotopni polimer
CA2225189C (en) 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
DE69838552T2 (de) 1997-07-14 2008-05-21 Bolder Biotechnology, Inc., Louisville Derivate des wachstumshormons und verwandte proteine
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
EP1023078A4 (en) * 1997-10-17 2004-09-29 Harvest Technologies Corp PRECIPITATION OF A FIBRINOGEN CONCENTRATE ENRICHED WITH A GROWTH FACTOR OBTAINED FROM A PLASMA ENRICHED PLASMA
EP0922446A1 (en) 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Solution-phase site-specific preparation of GRF-PEG conjugates
CA2329768C (en) 1998-04-27 2008-06-10 Opperbas Holding B.V. Pharmaceutical composition comprising factor viii and neutral liposomes
US6759216B1 (en) 1998-11-06 2004-07-06 Emory University Glycosylated, low antigenicity low immunogenicity factor VIII
PT1129186E (pt) 1998-11-10 2007-12-07 Sanquin Bloedvoorziening Um polipéptido factor viii com actividade de factor viii-c
US6358703B1 (en) 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
US6136599A (en) 1998-12-10 2000-10-24 Bayer Corporation Human hybrid host cell for mammalian gene expression
NZ513077A (en) 1999-01-14 2004-03-26 Bolder Biotechnology Inc Methods for making proteins containing free cysteine residues
AU5282200A (en) 1999-05-24 2000-12-12 American National Red Cross, The Methods of reducing factor viii clearance and compositions therefor
CA2739933A1 (en) * 2000-02-11 2001-08-16 Bayer Healthcare Llc Factor vii or viia-like molecules
EP1319016A4 (en) 2000-09-19 2006-05-10 Univ Emory MODIFIED FACTOR VIII
JP2005518181A (ja) 2001-01-12 2005-06-23 ジ・アメリカン・ナショナル・レッド・クロス 第ｖｉｉｉ因子のヘパラン硫酸プロテオグリカン仲介性クリアランスを低下させるための方法および組成物
KR20030085041A (ko) * 2001-03-22 2003-11-01 노보 노르디스크 헬스 케어 악티엔게젤샤프트 응고 인자 ⅶ 유도체
WO2002096454A1 (en) 2001-05-31 2002-12-05 D. Collen Research Foundation Vzw Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
AU2002312660A1 (en) 2001-05-31 2002-12-16 D. Collen Research Foundation Vzw Onderwijsen Navorsing Campus Gasthuisberg K.U. Leuven Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
CA2450732A1 (en) 2001-06-14 2002-12-27 John H. Griffin Stabilized proteins with engineered disulfide bonds
ES2319745T3 (es) 2001-10-05 2009-05-12 Expression Therapeutics, Llc Secuencias de acidos nucleicos y aminoacidos que codifican polipeptidos de factor viii de alto nivel de expresion, y metodos de uso.
RU2004133761A (ru) 2002-04-18 2005-07-10 Мерк Патент ГмбХ (DE) Модифицированный фактор viii
JP4412461B2 (ja) 2002-11-20 2010-02-10 日油株式会社 修飾された生体関連物質、その製造方法および中間体
US8003117B2 (en) 2002-11-20 2011-08-23 Nof Corporation Polyalkylene glycol derivative and modified bio-related substance
US7432330B2 (en) 2002-12-31 2008-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
KR101031206B1 (ko) 2002-12-31 2011-04-27 넥타르 테라퓨틱스 말레암산 중합체 유도체 및 이의 바이오컨쥬게이트
DE602004029646D1 (en) 2003-01-06 2010-12-02 Nektar Therapeutics San Carlos Thiolselektive wasserlösliche polymerderivate
MXPA05009169A (es) 2003-02-26 2005-11-17 Nektar Therapeutics Al Corp Conjugados de polimero-porcion del factor viii.
US20050176108A1 (en) 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
US20040180054A1 (en) 2003-03-13 2004-09-16 Hanmi Pharm. Co., Ltd. Physiologically active polypeptide conjugate having prolonged in vivo half-life
EA010016B1 (ru) 2003-05-12 2008-06-30 Афимакс, Инк. Новые модифицированные полиэтиленгликолем соединения и их применение
EP1626741A2 (en) 2003-05-23 2006-02-22 Nektar Therapeutics Al, Corporation Peg derivatives having an amidocarbonate linkage
EP1502921A1 (en) 2003-07-29 2005-02-02 ZLB Behring GmbH Recombinant mutated human factor VIII (FVIII) with improved stability
US20050123997A1 (en) 2003-10-30 2005-06-09 Lollar John S. Modified fVIII having reduced immunogenicity through mutagenesis of A2 and C2 epitopes
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
DE602004026474D1 (de) 2003-12-03 2010-05-20 Univ Rochester Rekombinanter faktor viii mit erhöhter spezifischer aktivität
WO2006027111A1 (en) 2004-09-06 2006-03-16 Zlb Behring Gmbh Modified coagulation factor viii with enhanced stability
MX350293B (es) 2004-11-12 2017-09-04 Bayer Healthcare Llc Modificacion dirigida al sitio del factor viii.
JP2008534559A (ja) 2005-04-01 2008-08-28 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 血液凝固ｆｖｉｉｉ類似体
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
NZ572050A (en) 2006-03-31 2011-09-30 Baxter Int Factor VIII conjugated to polyethylene glycol

Also Published As

Publication number Publication date
BRPI0517795A (pt) 2008-10-21
PL1824988T3 (pl) 2018-01-31
EP3153181A1 (en) 2017-04-12
WO2006053299A2 (en) 2006-05-18
KR20140019489A (ko) 2014-02-14
HUE033776T2 (en) 2018-01-29
WO2006053299A3 (en) 2006-08-24
BE2019C523I2 (forum.php) 2025-02-10
BRPI0517795B8 (pt) 2021-05-25
EP2363414A2 (en) 2011-09-07
EP2371856A2 (en) 2011-10-05
ES2930143T3 (es) 2022-12-07
ZA200703696B (en) 2008-08-27
BRPI0517795A8 (pt) 2018-12-26
PL2371856T3 (pl) 2022-08-22
EP3243834A1 (en) 2017-11-15
HRP20180481A2 (hr) 2018-06-29
DK2363414T3 (da) 2022-08-08
CN103102406A (zh) 2013-05-15
CN101124331A (zh) 2008-02-13
US20160051633A1 (en) 2016-02-25
ES2633916T3 (es) 2017-09-26
PT3130601T (pt) 2020-10-01
HRP20180481B1 (hr) 2022-02-18
HK1117875A1 (en) 2009-01-23
LTPA2019509I1 (lt) 2019-08-26
MX2007005466A (es) 2007-10-19
KR20120136413A (ko) 2012-12-18
NL300989I2 (nl) 2019-11-28
HUE059193T2 (hu) 2022-10-28
KR101904630B1 (ko) 2018-10-04
HUE060016T2 (hu) 2023-01-28
IL182903A0 (en) 2007-08-19
NO20072997L (no) 2007-06-27
SI3130601T1 (sl) 2020-11-30
EP3243833B1 (en) 2020-06-17
DK1824988T3 (en) 2017-08-07
PT2363414T (pt) 2022-08-04
LT3130601T (lt) 2020-09-10
RU2423380C2 (ru) 2011-07-10
EP1824988B1 (en) 2017-04-19
KR20130036780A (ko) 2013-04-12
LT1824988T (lt) 2017-10-25
US9096656B2 (en) 2015-08-04
EP1824988A4 (en) 2008-12-31
CN105148287B (zh) 2019-07-09
KR101654011B1 (ko) 2016-09-05
US7632921B2 (en) 2009-12-15
PT1824988T (pt) 2017-07-21
US20100081615A1 (en) 2010-04-01
HK1182121A1 (en) 2013-11-22
BRPI0517795B1 (pt) 2020-03-31
CA2586379A1 (en) 2006-05-18
FR19C1031I1 (forum.php) 2019-06-28
UA95225C2 (ru) 2011-07-25
US20060115876A1 (en) 2006-06-01
AU2005304622B2 (en) 2012-03-29
JP6018238B2 (ja) 2016-11-02
KR20070110260A (ko) 2007-11-16
HK1218718A1 (zh) 2017-03-10
PT2371856T (pt) 2022-08-12
PH12019501613A1 (en) 2020-09-14
EP2371856B1 (en) 2022-05-18
PH12014500352B1 (en) 2019-09-25
CN103214569B (zh) 2016-12-28
KR20160105928A (ko) 2016-09-07
CN103102406B (zh) 2015-05-27
FR19C1031I2 (fr) 2020-06-05
NO344606B1 (no) 2020-02-10
EP3243833A1 (en) 2017-11-15
ES2930159T3 (es) 2022-12-07
DK2371856T3 (en) 2022-08-08
JP6109523B2 (ja) 2017-04-05
US20130274445A1 (en) 2013-10-17
US9364520B2 (en) 2016-06-14
HRP20070268A2 (hr) 2007-09-30
JP2008524117A (ja) 2008-07-10
HUS1900026I1 (hu) 2022-04-28
LT2371856T (lt) 2022-08-25
KR101243564B1 (ko) 2013-03-27
EP2371856A3 (en) 2012-03-14
CN103214569A (zh) 2013-07-24
IL232540A0 (en) 2014-06-30
HRP20070268B1 (hr) 2018-04-20
PH12014500352A1 (en) 2015-07-20
EP3323829B1 (en) 2020-07-15
EP3130601B1 (en) 2020-07-15
IL182903A (en) 2014-09-30
EP2772500A1 (en) 2014-09-03
CN105753968A (zh) 2016-07-13
AU2005304622A1 (en) 2006-05-18
BR122016022033B1 (pt) 2021-03-02
CN105148287A (zh) 2015-12-16
LTC1824988I2 (lt) 2021-02-25
NO20200044A1 (no) 2007-06-27
CY1119292T1 (el) 2018-02-14
NO345800B1 (no) 2021-08-09
LT2363414T (lt) 2022-10-25
MX350293B (es) 2017-09-04
SI1824988T1 (sl) 2017-11-30
LUC00118I1 (forum.php) 2019-05-13
CY2019024I1 (el) 2019-11-27
BR122016022033B8 (pt) 2021-05-25
JP6487895B2 (ja) 2019-03-20
KR101468345B1 (ko) 2014-12-03
KR20180110192A (ko) 2018-10-08
SI2371856T1 (sl) 2022-09-30
JP6559642B2 (ja) 2019-08-14
LUC00118I2 (forum.php) 2019-12-27
CY2019024I2 (el) 2019-11-27
PL2363414T3 (pl) 2022-09-05
KR20140091618A (ko) 2014-07-21
NL300989I1 (nl) 2019-05-22
CN107082806A (zh) 2017-08-22
EP2772500B1 (en) 2019-12-25
JP2017105773A (ja) 2017-06-15
CN101124331B (zh) 2013-04-24
EP2363414A3 (en) 2012-03-21
EP1824988A2 (en) 2007-08-29
JP2013067621A (ja) 2013-04-18
NO20210454A1 (no) 2007-06-27
SI2363414T1 (sl) 2022-09-30
MX392760B (es) 2025-03-24
HN2007015683A (es) 2011-07-11
KR101483917B1 (ko) 2015-01-16
EP3323829A1 (en) 2018-05-23
IL234433B (en) 2019-11-28
JP2017101028A (ja) 2017-06-08
CY1123384T1 (el) 2021-12-31
EP3130601A1 (en) 2017-02-15
RU2007121517A (ru) 2008-12-20
CA2586379C (en) 2012-04-03
HUE050542T2 (hu) 2020-12-28
IL232540A (en) 2017-08-31
NZ555032A (en) 2010-02-26
JP2015134780A (ja) 2015-07-27
ES2821832T3 (es) 2021-04-27
EP2363414B1 (en) 2022-05-18

Similar Documents

Publication Publication Date Title
MA29663B1 (fr) Modification du facteur fviii en fonction du site
DK1487493T3 (da) Konjugater af cytotoksiske midler og biologisk aktive peptider
DE60315454D1 (de) Blockcopolymere auf basis von konjugierten dienen und monovinylarenen enthaltende mischungen
ATE490275T1 (de) Antikörper gegen interleukin-22 und verwendungen dafür
IL181473A (en) Antibodies @ people @ against @@@ beta @@ preparations that include them and use them
DK1419154T3 (da) Rapamycin-29-enoler
TW200602079A (en) Immunoglobulins
NO20034056D0 (no) Proliferative sykdommer
CY1113798T1 (el) Υποκατεστημενες ενωσεις διαζεπανης ως ανταγωνιστες υποδοχεα ορεξινης
ATE463505T1 (de) Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren
TR200102733T2 (tr) IL-18 kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri
DK1353689T3 (da) Immuniseringspræparater og anvendelse deraf
BRPI0207933B8 (pt) polipeptídeo mutante de interleucina-18 e composição farmacêutica
CY1116415T1 (el) Φαρμακευτικες συνθεσεις που περιλαμβανουν l-733060 για χρηση στη θεραπευτικη αγωγη καρκινικων ογκων
IL209338A0 (en) Pharmaceutical compositions containing anti-cd-3 antibodies
MXPA05013509A (es) Polipeptidos de fusion de variante ib alfa de glucoproteina de plaquetas y metodos y uso de los mismos.
ATE409045T1 (de) Pharmazeutische zusammensetzung enthaltend löslichen fcgamma rezeptor iib
MY134019A (en) Aryl oxime-piperazines useful as ccr5 antagonists
DE60319135D1 (de) Peptide, die die heparinbindungsdomäne von vegf und vegfr-2 binden
WO2006065867A3 (en) Polymer-linked pseudomonas exotoxin immunotoxin
EA200600314A1 (ru) Использование растворимого cd164 при воспалительных и/или аутоимунных нарушениях
FR2832155B1 (fr) Anticorps stimulant la production d'il-1ra
MXPA01009174A (es) Antagonistas de endotelina novedosos derivados de piridazina.
ITFI20030238A1 (it) Peptidi ciclici antagonisti dell'urotensina-ii